Sciformix Executives Drive Agenda on Achieving Drug Safety Excellence at World Drug Safety Congress
News Mar 28, 2013
Sciformix Corporation has announced its premium sponsorship of the 5th annual World Drug Safety Congress, taking place from April 24 - 25, 2013 at the Revere Hotel Boston Common, Boston, USA.
The World Drug Safety Congress addresses strategic and crucial issues in the development and execution of drug safety programs.
Senior executives of Sciformix, will be chairing the opening session and setting the stage on how organizations can stay on top of international regulatory requirements and streamline their drug safety programs.
Sciformix, premium sponsors of the event for the third year in a row, continues its success in its global delivery of services and solutions in Safety and Risk Management.
Their scientific and safety experts work closely with the top global pharmaceutical and biopharmaceutical, generics, consumer product and medical devices organizations to support their safety needs throughout the entire product lifecycle.
With substantial growth in business year on year, Sciformix is taking its position as a leader in drug safety services.
The World Drug Safety Congress aims to present innovative solutions to the key safety challenges facing both pharmaceutical industry and pharmacovigilance professionals worldwide.
It brings together senior personnel from a range of global pharmaceutical companies, regulatory agencies and academic institutions to share their expertise in the drug safety arena.
The conference provides an excellent opportunity for attendees to discuss diverse issues related to drug safety with specialists and practitioners.
At the conference, Sciformix will be demonstrating its expertise by engaging with the speakers and delegates, sharing their knowledge of key developments in the global drug safety market, and demonstrating solutions that provide competitive advantage to participating companies.
Manish Soman, President and CEO comments “We are delighted to be a part of the World Drug Safety Congress. Our support of the event is part of our ongoing investment in the field of drug safety. We want to share the knowledge we have gained while working with clients over the years, which has been incorporated into our innovative methodology and approaches to the problems of drug safety and risk management”.
To help drug safety professionals achieve excellence, world renowned expert Sidney Kahn, Senior Principal Pharmacovigilance Practice at Sciformix, will be addressing the audience with his keynote presentation on “The challenges in achieving excellence in the rapidly evolving global drug safety environment”.
On the second day of the conference, Chitra Lele, Chief Scientific Officer and co-founder at Sciformix will host an in-depth presentation and panellist discussion on “Taking the noise out of signal detection”.
Experts including Ram Tiwari, Ph.D., Associate Director, Office of Biostatistics, Center for Drug Evaluation & Research, US FDA and Michael Sprafka, Executive Director of Observation Research, Head of Pharmacovigilance-Epidemiology, Amgen, will provide practical solutions to the problems of inadequacies of available quantitative measures and indicate possible enhancements of the method during an informative and thought provoking presentation and panel discussion.
Sciformix partners with their clients through the entire drug development cycle, to provide a full range of services from study design to post marketing surveillance and commercialization support.
Areas of specialization include Safety and Risk Management, Clinical Research & Post Approval Services, Medical Affairs, Scientific Writing and Regulatory Affairs.
Children With Congenital Zika Virus Infection Face Serious Challenges as They AgeNews
The report from the CDC is the first to describe the health and developmental effects of congenital Zika virus infection in children with microcephaly through 2 years of age.READ MORE
British Pharmacological Society’s Drug Discovery of the Year 2018 AnnouncedNews
A new medicine used to treat an ultra-rare inherited disorder which leaves babies without a fully functioning immune system has been named the British Pharmacological Society’s Drug Discovery of the Year 2018.READ MORE